![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
Alexander Edward Perl, MD, MS
Specialities: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia
Spoken languages: English
Clinical Expertise
- Acute Myeloid Leukemia
- Acute Lymphocytic Leukemia
- Myelodysplastic Syndromes
- Chronic Myeloid Leukemia
About
Dr. Alexander Perl is a member of the leukemia program in the Abramson Cancer Center and an Associate Professor in the Division of Hematology/Oncology at the Perelman School of Medicine at the University of Pennsylvania. His research focuses on molecularly-targeted therapeutics for acute leukemia. His principal expertise is in FLT3 inhibitors for AML and he has played a leading role in clinical trails of these agents. He also studies other agents targeting signal transduction, such as tyrosine kinase inhibitors for Ph-like ALL and inhibitors of oncogenic PI3K/AKT/mTOR signaling. His laboratory studies focus on phospho-specific flow cytometry of fixed, unfractionated blood and marrow as a method to quantify pharmacodynamic response to signal transduction inhibitors. He is additionally interested in preclinical drug screening in cellular and murine xenotransplantation models of acute leukemia.
Location
University Of Pennsylvania Abramson Cancer Center: Perelman Center for Advanced Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104, USA
Get the latest thought leadership on your Acute Lymphocytic Leukemia delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2024 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811